ClinicalTrials.gg
RecruitingNCT02602769Updated Oct 21, 2025

Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome

An observational study in Childhood Obesity and Morbid Obesity, sponsored by Columbia University. Recruiting at 2 sites in United States. Open to participants aged 2 Years to 20 Years. Per ClinicalTrials.gov, last updated 2025-10-21.

Sponsored by Columbia University · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
12
Ages
2 Years to 20 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 558 studies in Pediatric Obesity with a site in United States — 72 open to participants now, 109 under way, 3 of them phase 3. Pediatric Obesity · United States.

Planned enrollment
79th of 81
12 · median 120
Started
2015
with 21 others
Observational
82 of 558
13 open now
Primary completion
2026-12
later than 28 of 108 live
Registered
152nd of 558
by date

Among the 558 studies in Pediatric Obesity with a site in United States, this one is the 79th largest by planned enrollment of the 81 observational ones that give a count, is one of 22 that started in 2015, is one of 82 observational ones, reaches primary completion later than 28 of the 108 other live ones, and was the 152nd registered.

Pediatric Obesity

1,132 studies on the registry are indexed under Pediatric Obesity; 183 are open to participants now.

Browse Pediatric Obesity studies →

Open to participants now

72 of the 558 studies in Pediatric Obesity with a site in United States are open now. Recruiting first, the newest first:

67 more — sign in →

All 72 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 119 Pediatric Obesity studies recruiting now, 16 (13%) set no upper age limit and 101 (85%) stop at 75 or younger; 110 take children under 18; 67 take healthy volunteers.

This study: 2 Years to 20 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 558 studies in Pediatric Obesity with a site in United States, or all of them as a file.
02

Study summary

Rapid onset Obesity, Hypoventilation, Hypothalamic dysfunction and Autonomic Dysregulation (ROHHAD) is a syndrome named in 2007. The hallmark of the syndrome is the rapid onset obesity and dysregulation of central ventilation. There is little information about the metabolic changes that lead to the rapid onset obesity in these children. The investigators would like to study the metabolic phenotype of these children to understand the disturbances in energy balance that lead to the rapid onset obesity.

Read the detailed description

Late-onset hypoventilation syndrome with hypothalamic dysfunction was first described in 1965 and renamed to ROHHAD syndrome in 2007 by Ize-Ludlow et al.

The hallmark of ROHHAD syndrome is rapid-onset obesity starting at approximately 1.5 years of age with weight gain of 12-20 kg/year, central hypoventilation distinct from the obstructive hypoventilation caused by obesity, hyperphagia, a spectrum of pituitary hormonal dysfunction, and autonomic disturbances including temperature, blood pressure, and nociception abnormalities. Some children have been noted with developmental and behavioral abnormalities. Tumors of neural crest origin have been identified in 25-33% of the patients. The etiology of ROHHAD syndrome and the cause of rapid onset obesity is unknown.

The aims of this study are to understand the whole transcriptome profiling of patient specific induced pluripotent cell (iPSC) derived hypothalamic neurons to understand the transcriptional level changes that give rise to the manifestations seen in ROHHAD syndrome.

Aim 1. Generate patient specific iPSC-derived hypothalamic neurons from children with ROHHAD syndrome and their unaffected first degree relatives.

Aim 2: Compare the whole transcriptome profiling of the patient derived cells compared to those of unaffected relatives and reference datasets to understand the differences in transcriptome that gives rise to ROHHAD syndrome.

Aim 3: Selected patients may be invited to participate for detailed metabolic phenotyping to understand the mechanisms of excessive weight gain.

03

Conditions studied

  • Childhood Obesity
  • Morbid Obesity

Keywords

  • Hypoventilation syndrome
  • Hypothalamic dysfunction
  • Autonomic dysregulation
  • Rapid onsey obesity
04

Who can participate

Ages eligible
2 Years to 20 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Children diagnosed with ROHHAD (Rapid onset Obesity, Hypoventilation, Hypothalamic dysfunction, Autonomic Disturbances), and their first degree relatives.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children with ROHHAD syndrome

Exclusion criteria

Exclusion Criteria:

  • Children with known genetic causes of obesity
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
12 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Cases of ROHHAD syndrome

    Children diagnosed with ROHHAD syndrome during the course of their clinical care by their physicians. The investigators will perform transcriptome profiling in this group.

    Diagnostic Test: Transcriptome profiling

  • Control cohort

    Unaffected first degree family members. The investigators will perform transcriptome profiling in this group.

    Diagnostic Test: Transcriptome profiling

Interventions

  • Diagnostic testTranscriptome profiling

    The investigators will obtain blood to extract peripheral mononuclear cells. These cells will be used to generate patient specific hypothalamic cells that will be used for transcriptome profiling.

06

What researchers measure

Primary outcomes

  1. Changes in the transcriptome profile of hypothalamic cells of children with ROHHAD syndrome compared to their unaffected first degree relatives.

    The investigators will perform whole transcriptome profiling of iPSC-derived hypothalamic neurons and compare the whole genome sequencing to identify the changes that may give rise to the disease.

    Time frame: 2 year

07

Study locations

1 of 2 sites recruiting
08

References and documents

Publications

  • Thaker VV, Esteves KM, Towne MC, Brownstein CA, James PM, Crowley L, Hirschhorn JN, Elsea SH, Beggs AH, Picker J, Agrawal PB. Whole exome sequencing identifies RAI1 mutation in a morbidly obese child diagnosed with ROHHAD syndrome. J Clin Endocrinol Metab. 2015 May;100(5):1723-30. doi: 10.1210/jc.2014-4215. Epub 2015 Mar 17. PubMed 25781356 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2015, a primary completion of Dec 2026 and a completion of Dec 2026. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2015
First posted
Nov 11, 2015
Start
Nov 2015
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Oct 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02602769
Responsible party
Vidhu V. Thaker (Assistant Professor, Columbia University) — Principal investigator
First posted
Nov 11, 2015
Start date
Nov 2015
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Oct 21, 2025

Study contacts

Vidhu Thaker, MD
Contact
vvt2114@cumc.columbia.edu
2128515315
Vidhu Thaker, MD
principal investigator · Columbia University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion